All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Consensus-based guidelines for the management of patients with AML in Gulf Cooperation Council countries
|
Consensus-based guidelines for the management of patients with acute myeloid leukemia (AML) in Gulf Cooperation Council (GCC) countries were published in the Journal of Clinical Oncology Global Oncology by Al-Khabori et al.1 These guidelines were developed by 10 panel members from four GCC countries: Kuwait, Oman, Qatar, and the United Arab Emirates, using a modified two-round Delphi process.1 The panel developed consensus guidelines to address region-specific challenges in the management of patients with AML.1 |
| Key learnings |
| The expert opinion-based consensus guidelines provide evidence-based diagnostic workflow and treatment algorithms for patients with AML in GCC countries. |
| The panel recommended using the European LeukemiaNet (ELN) 2022 recommendations for assessing AML subtype, therapy decision-making, and risk stratification. |
| The panel recommended the use of measurable residual disease (MRD) assessments in patients with specific mutations to predict relapse risk, while also highlighting the significant challenge of the turnaround time of laboratory resources in GCC countries. |
| The panel supported using tailored fitness criteria for induction chemotherapy, reflecting the variability in patient fitness levels between GCC countries and other regions, particularly in older patients. |
| For patients with relapsed/refractory AML, the panel suggested venetoclax-hypomethylating drugs; fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor; and targeted therapy. |
| The panel recommended prophylaxis treatment with broad spectrum antibiotics for preventing infections in patients treated with venetoclax and undergoing remission induction therapy. |
| The panel highlighted the need for improving healthcare infrastructure in GCC countries, including enhancing access to molecular genetics laboratories and addressing disparities in healthcare accessibility and insurance coverage. |
| Implementing these consensus guidelines can enhance clinical decision-making and patient outcomes in GCC countries by promoting standardized practices and facilitating patient participation in international clinical trials, potentially improving patient care through evidence-based, regionally adapted guidelines. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
